Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Anthracyclines / Trastuzumab: new aspects of cardiotoxicity and molecular mechanisms

Abstract : Anticancer drugs continue to cause significant reductions in left ventricular ejection fraction resulting in congestive heart failure. The best-known cardiotoxic agents are anthracyclines such as doxorubicin. For several decades, cardiotoxicity was almost exclusively associated with anthracyclines, for which cumulative dose-related cardiac damage was the use-limiting step. Human epidermal growth factor receptor 2 (HER2; ErbB2) has been identified as an important target for breast cancer. Trastuzumab (TRZ), a humanized anti-HER2 monoclonal antibody, is currently recommended as first-line treatment for patients with metastatic HER2+ tumours. The use of TRZ may be limited by the development of drug intolerance, such as cardiac dysfunction. Cardiotoxicity has been attributed to free-iron-based, radical-induced oxidative stress. Many approaches have been promoted to minimize these serious side effects, but they are still clinically problematic. A new approach to personalized medicine for cancer that involves molecular screening for clinically relevant genomic alterations and genotype-targeted treatments is emerging.
Liste complète des métadonnées
Contributeur : Catherine Vergely Connectez-vous pour contacter le contributeur
Soumis le : jeudi 18 novembre 2021 - 10:24:50
Dernière modification le : vendredi 20 mai 2022 - 09:06:35
Archivage à long terme le : : samedi 19 février 2022 - 18:32:41



Luc Rochette, Charles Guenancia, Aurélie Gudjoncik, Olivier Hachet, Marianne Zeller, et al.. Anthracyclines / Trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends in Pharmacological Sciences, Elsevier, 2015, 36 (6), pp.326-348. ⟨10.1016/⟩. ⟨hal-03434138⟩



Consultations de la notice


Téléchargements de fichiers